It’s remarkable that so called “ethical” pharmaceutical companies are anything but…..ethical. Johnson and Johnson and it’s DePuy Orthopedics division appear to have suppressed and/or ignored early information that the devices were faulty and would fail prematurely.
Johnson & Johnson never released those projections for the device, the Articular Surface Replacement, or A.S.R., which the company recalled in mid-2010. But at the same time that the medical products giant was performing that analysis, it was publicly playing down similar findings from a British implant registry about the device’s early failure rate.
The company’s analysis also suggests that the implant is likely to fail prematurely over the next few years in thousands more patients in addition to those who have already had painful and costly procedures to replace it.
Medicynical Note: As we’ve noted before these companies are not about patient care or good outcomes. They are about the money.